Altimmune Inc ALT:NASDAQ

Last Price$9.48NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$9.45 (2)
Ask (Size)$9.58 (10)
Day Low / HighN/A - N/A
Volume836.7 K

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Altimmune Inc ( NASDAQ )

Price: $9.48
Change: -0.64 (6.32%)
Volume: 836.7 K
4:00PM ET 12/03/2021

Information Services Group Inc ( NASDAQ )

Price: $7.90
Change: -0.20 (2.47%)
Volume: 244.5 K
4:00PM ET 12/03/2021

Comtex News Network Inc ( OTC )

Price: $20.02
Change: 0.00 (0.00%)
Volume: 1.00
9:30AM ET 9/22/2021

Emerald Holding Inc ( NYSE )

Price: $4.02
Change: -0.14 (3.37%)
Volume: 85.7 K
7:00PM ET 12/03/2021

Atomera Inc ( NASDAQ )

Price: $20.35
Change: -1.28 (5.92%)
Volume: 463.0 K
4:00PM ET 12/03/2021

Read more news Recent News

-- Earnings Flash (ALT) ALTIMMUNE Posts Q3 Revenue $0.2M, vs. Street Est of $0.071M
4:05PM ET 11/09/2021 MT Newswires


Altimmune Enrolls First Patient in Fatty Liver Disease Trial
8:30AM ET 10/04/2021 MT Newswires

Altimmune (ALT) said Monday it has enrolled the first patient in an early-stage trial of pemvidutide as a potential treatment for non-alcoholic fatty liver...

Sector Update: Health Care Stocks Decline Premarket Tuesday
9:13AM ET 9/28/2021 MT Newswires

Health care stocks were declining in Tuesday's premarket trading. The Health Care SPDR (XLV) was 0.63% lower and the iShares NASDAQ Biotechnology Index...

Sector Update: Health Care
8:55AM ET 9/28/2021 MT Newswires

Health care stocks were declining in Tuesday's premarket trading. The Health Care SPDR (XLV) was 0.7% lower and the iShares NASDAQ Biotechnology Index...

Company Profile

Business DescriptionAltimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV). The company was founded in 1997 and is headquartered in Gaithersburg, MD. View company web site for more details
Address910 Clopper Road
Gaithersburg, Maryland 20878
Number of Employees27
Recent SEC Filing12/01/20214
President, Chief Executive Officer & DirectorVipin K. Garg
Secretary, Chief Financial & Accounting OfficerWilliam M. Brown
Chief Scientific OfficerM. Scot Roberts
Chief Technology OfficerBertrand Georges

Company Highlights

Price Open$10.20
Previous Close$10.12
52 Week Range$8.10 - 24.61
Market Capitalization$376.7 M
Shares Outstanding39.7 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.91
Beta vs. S&P 500N/A
Revenue$10.3 M
Net Profit Margin-2,432.90%
Return on Equity-36.33%

Analyst Ratings as of 06/01/2021

Consensus RecommendationConsensus Icon
Powered by Factset